Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis



Shaygannezhad V1 ; Amini H2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neuroscienseces Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2017

Abstract

Background: The aim of this study was to determine the efficacy of monthly cyclophosphamide and daily fingolimod in treatment of patients with multiple sclerosis (MS) and to compare these two treatment strategies. Methods: In a clinical trial study, 30 patients with relapsing remitting multiple sclerosis (RRMS) were enrolled. 15 patients were treated by cyclophosphamide and 15 by fingolimod for six months. The expanded disability status scale (EDSS) score and relapse rate were measured and compared between the two groups. Findings: The mean differences of EDSS in the two groups were -0.03 ± 0.17 and 0.33 ± 0.18, respectively and the decrease of EDSS in fingolimod group was significantly higher than the cyclophosphamide group (P < 0.001). In the cyclophosphamide group, there were 4 patients without recurrence, 10 single and 1 double flares; while in fingolimod group, only 4 patients had a single relapse. The differences in after-treatment relapses among the two groups was statistically significant (P = 0.023). Conclusion: Using daily fingolimod is better than the cyclophosphamide for prevention of relapse and improvement of EDSS in patients with relapsing remitting multiple sclerosis; but treatment of multiple sclerosis with this drug depend on patient's clinical status, intensity of the disease, and idea of neurologist. However, more studies are recommended for determining the side effects in long term use of fingolimod. © 2017, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
2. Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis, BMC Medical Research Methodology (2022)
3. Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis, Acta Medica Iranica (2019)
4. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis in the United Kingdom, Journal of Medical Economics (2024)
5. Diagnosis and Management of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2016)
6. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
7. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
8. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (106)
Masoud Etemadifar (85)
Other Related Docs
9. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
10. Early Non-Disabling Relapses Are Important Predictors of Disability Accumulation in People With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis Journal (2023)
11. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
12. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
13. Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients, International Journal of Preventive Medicine (2015)
14. Mycophenolate Mofetil in Combination With Interferon Beta-1A in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Preliminary Study, Journal of Research in Medical Sciences (2011)
15. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
16. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
17. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
18. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
19. The Outbreak Fingolimod Cardiovascular Side Effects in Relapsing-Remitting Multiple Sclerosis Patient: A Longitudinal Study in an Iranian Population, ARYA Atherosclerosis (2016)
20. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
21. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
22. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
23. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
24. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
25. Contribution of Different Relapse Phenotypes to Disability in Multiple Sclerosis, Multiple Sclerosis (2017)
26. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
27. Iranian Specialists’ Approach to Surgery in Patients With Multiple Sclerosis, Current Journal of Neurology (2023)
28. Protocol of a Prospective Multicenter Study on Comorbidity Impact on Multiple Sclerosis and Antibody-Mediated Diseases of the Central Nervous System (Commit), Frontiers in Immunology (2024)
29. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
30. Does Early-Onset Multiple Sclerosis Differ From Adult-Onset Form in Iranian People, Journal of Research in Medical Sciences (2010)
31. Promising Effect of Rapamycin on Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2018)
32. Mizaj Assessment in Multiple Sclerosis (Ms) Patients Based on Persian Medicine, Journal of Complementary and Integrative Medicine (2022)
33. Mri Features and Disability in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Journal of Neuroradiology (2024)
34. Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis: A Phase Iii, Randomized, Equivalency, Clinical Trial, Scientific Reports (2024)
35. Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2018)
36. Seasonal and Monthly Variation in Multiple Sclerosis Relapses: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2022)
37. Mitoxantrone Reduced Disability in Iranian Patients With Multiple Sclerosis, Archives of Iranian Medicine (2007)
38. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
39. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
40. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
41. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
42. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
43. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
44. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
45. Early Clinical Response and Complications of Therapeutic Plasma Exchange in Central Nervous System Demyelinating Diseases, Journal of Central Nervous System Disease (2024)
46. Tumefactive Rebound of Multiple Sclerosis After the Short-Term Cessation of Fingolimod: A Case Report, Multiple Sclerosis and Related Disorders (2020)
47. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
48. Predictors of Treatment Switching in the Big Multiple Sclerosis Data Network, Frontiers in Neurology (2023)
49. Sex As a Determinant of Relapse Incidence and Progressive Course of Multiple Sclerosis, Brain (2013)
50. Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial, International Journal of Preventive Medicine (2020)